



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from *Vernonia amygdalina* and *Occimum gratissimum*

Gideon A. Gyebi<sup>a</sup>, Abdo A. Elfiky<sup>b, \*\*</sup>, Oludare M. Ogunyemi<sup>c, \*</sup>, Ibrahim M. Ibrahim<sup>b</sup>, Adegbenro P. Adegunloye<sup>d</sup>, Joseph O. Adebayo<sup>d</sup>, Charles O. Olaiya<sup>e</sup>, Joshua O. Ocheje<sup>c</sup>, Modupe M. Fabusiwa<sup>c</sup>

<sup>a</sup> Department of Biochemistry, Faculty of Science and Technology, Bingham University, Karu, Nasarawa, Nigeria

<sup>b</sup> Department of Biophysics, Faculty of Sciences, Cairo University, Giza, Egypt

<sup>c</sup> Human Nutraceuticals and Bioinformatics Research Unit, Department of Biochemistry, Salem University, Nigeria

<sup>d</sup> Department of Biochemistry, Faculty of Life Sciences, University of Ilorin, Ilorin, Nigeria

<sup>e</sup> Nutritional and Industrial Biochemistry Research Unit, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, 200005, Nigeria

### ARTICLE INFO

#### Keywords:

Food herbs  
Coronavirus  
COVID-19  
Phytochemicals  
Terpenoids  
Molecular docking  
Molecular dynamics simulations

### ABSTRACT

Antiviral culinary plants are potential bioresources for preventive nutraceuticals and/or antiviral drugs in COVID-19. Structure-based virtual screening was undertaken to screen 173 compounds previously reported from *Vernonia amygdalina* and *Occimum gratissimum* for direct interaction with the active site of the 3-Chymotrypsin-Like Protease (3CL<sup>Pro</sup>) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on docking scores and comparison with reference inhibitors, a hit-list of 10 top phytocompounds was defined, which also had strong interactions with the catalytic centre of 3CL<sup>Pro</sup> from three related strains of coronavirus (SARS-CoV, MERS-CoV, HKU4). Among these, six compounds (neoandrographolide, vernolide, isorhamnetin, chicoric acid, luteolin, and myricetin) exhibited the highest binding tendencies to the equilibrated conformers of SARS-CoV-2 3CL<sup>Pro</sup> in an in-depth docking analysis to 5 different representative conformations from the cluster analysis of the molecular dynamics simulation (MDS) trajectories of the protein. *In silico* drug-likeness analyses revealed two drug-like terpenoids viz: neoandrographolide and vernolide as promising inhibitors of SARS-CoV-2 3CL<sup>Pro</sup>. These structures were accommodated within the substrate-binding pocket; and interacted with the catalytic dyad (Cys<sup>145</sup> and His<sup>41</sup>), the oxyanion loop (residues 138–145), and the S1/S2 sub-sites of the enzyme active site through the formation of an array of hydrogen bonds and hydrophobic interactions. Molecular dynamics simulation and binding free energy calculation revealed that the terpenoid-enzyme complexes exhibit strong interactions and structural stability. Therefore, these compounds may stabilize the conformation of the flexible oxyanion loop; and thereby interfere with the tetrahedral oxyanion intermediate formation during the proteolytic activity of the enzyme.

### 1. Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current global health crisis called coronavirus disease 2019 (COVID-19). Coronavirus infections have been life-threatening and difficult to treat due to their rapid outbreak, ease of adaptation, emergence of new and resistant viral strains and the

inapplicability of antibiotics [1]. SARS-CoV-2 was shown to share a close genome sequence with previously reported strains such as SARS-CoV, MERS-CoV, and HKU4, mostly in the open reading frame a (ORF1a) [2]. Hence, SARS-CoV-2 has been clustered with beta-coronavirus genera, including SARS and SARS-like coronaviruses. The genome of SARS-CoV-2 contains a positive-sense, single-stranded RNA of about 30 kb size [3]. It is made up of a number of ORFs, with the first ORF being

\* Corresponding author. Human Nutraceuticals and Bioinformatics Research Unit, Department of Biochemistry, College of Natural and Applied Sciences, Salem University, PMB 1060, Lokoja, Nigeria.

\*\* Corresponding author. Faculty of Sciences, Department of Biophysics Cairo University, Giza, Egypt.

E-mail addresses: [abdo@sci.cu.edu.eg](mailto:abdo@sci.cu.edu.eg) (A.A. Elfiky), [ogunyemi.michael@salemuniversity.edu.ng](mailto:ogunyemi.michael@salemuniversity.edu.ng) (O.M. Ogunyemi).

<https://doi.org/10.1016/j.combiomed.2021.104671>

Received 18 April 2021; Received in revised form 12 July 2021; Accepted 17 July 2021

Available online 21 July 2021

0010-4825/© 2021 Elsevier Ltd. All rights reserved.

the largest, representing about 66 % of the genome [4]. During viral infection of host cell, the genome of the virus is emptied into host cell. This is followed by translation of the genomic content using the host's ribosomes to generate the viral structural and non-structural proteins [5]. The first ORF results in about 16 non-structural proteins (nsps), including the non-structural protein 5 (nsp5), also called 3-Chymotrypsin-like protease (3CL<sup>pro</sup>). The protease 3CL<sup>pro</sup> consists of 306 amino acid residues, ranging from amino acid 3264 to amino acid 3569 of the polyprotein 1 ab.

The 3-Chymotrypsin-like protease (3CL<sup>pro</sup>) is a cysteine protease that facilitates the proteolytic processing of the viral polyproteins to yield functional proteins essential for the packaging of new virions [6]. It is one of the most important components of viral replication as it cleaves the replicase polyprotein after its translation at 11 different sites releasing most of the functional protein components of the replicase-transcriptase complex, hence it is also known as main protease (M<sup>pro</sup>) of coronaviruses [7]. Amino acid sequence alignments of this protease revealed that, SARS-CoV-2 3CL<sup>pro</sup> had ~96 % sequence identity with the previous SARS-CoV 3CL<sup>pro</sup>, and ~50 % sequence identity with MERS-CoV 3CL<sup>pro</sup> [8]. Its substrate specificity is primarily defined by the residues at the P1, P1' and P2 positions of the peptide substrate. These positions are highly conserved in all coronaviruses in particular the presence of glutamine at the P1 position (N-terminus of the scissile bond) of the substrate is strictly required for 3CL<sup>pro</sup> binding across all coronaviruses [7]. Inhibition of 3CL<sup>pro</sup> by compounds is not expected to interfere with human proteases since the protease has no homologue in human [6]. In addition, since 3CL<sup>pro</sup>, plays critical role in the survival, replication and infectivity of SARS-CoV-2, it is an attractive drug target [9]. Inhibitors of this protease such as lopinavir and ritonavir, used for the treatment of HIV are reported for their potential use against COVID-19 [10].

While drug repurposing towards targeting important proteins in SARS-CoV-2 are still under development, considerable volume of scientific evidence suggest that novel natural compounds with potential antiviral activities can be deployed against SARS-CoV-2 [11–13]. Studies have revealed that such compounds from indigenous herbs and medicinal plants may inhibit replication of coronaviruses, especially SARS-CoV-2 [14–16]. African tea leaf (*Vernonia amygdalina* Del.), is a small shrub growing predominantly in tropical Africa widely used for culinary purposes [17,18]. This plant has been used earlier in Western Africa against several viral diseases [19,20]. African basil (*Occimum gratissimum*), a culinary herb with strong spicy flavour widely consumed in West Africa, is known to exhibit a wide range of biological roles including antiviral activities [21]. *In vitro* studies showed that its leaf extract inhibited HIV-1 and HIV-2 replication with antiviral indices of 110 [22]. These culinary herbs alongside others with well documented antiviral activities such as *Aframomum melagueta* and *Piper guineense* have been suggested as potential bioresources for preventive nutraceuticals and antiviral drugs against COVID-19 [23,24].

Structure-based virtual screening (SBVS) has been widely employed to search chemical compound libraries towards bioprospecting novel bioactive molecules against viral drug targets in the on-going campaign against coronavirus pandemic [25,26]. It is a fast, environmentally sound, and cost effective approach used in early-stage of drug discovery process [27]. In this technique, a dataset of compounds is docked into the binding site of the three-dimensional (3D) structure of the biological target obtained from X-ray, NMR, or computational modelling, in order to select a subset of these compounds based on the predicted binding scores for further biological evaluation. Rapid identification and documentation of antiviral structures from widely consumed African antiviral culinary herbs and spices such as *Vernonia amygdalina* and *Occimum gratissimum* may help to support the current drive towards developing safe, accessible and economically feasible antiviral preparations to be used as home-grown preventive nutraceuticals, food supplements, and antiviral drugs against the pandemic. Therefore, this study was carried out to screen an in-house library of 173 compounds from *Vernonia*

**Table 1**

Binding site coordinates of 3-Chymotrypsin-like protease of Coronaviruses.

Dimensions	SARS-CoV-2 (Å)	SARS-CoV (Å)	MERS-CoV (Å)	HKU4 (Å)
center_x	11.06	44.40	35.38	29.28
center_y	4.06	14.71	21.37	44.91
center_z	14.93	11.43	38.10	16.60
Size x	18.50	23.16	20.37	20.89
Size y	23.02	18.95	15.65	18.37
Size z	23.02	21.66	20.38	20.47

*amygdalina* and *Occimum gratissimum* for druggable phytochemicals with direct interactions with the active site of SARS-CoV-2 3CL<sup>pro</sup> in silico.

## 2. Materials and methods

### 2.1. Retrieval and preparation of protein structure for molecular docking

The recently published three-dimensional structure of 3CL<sup>pro</sup> of SARS-CoV-2 (PDB ID: 6Y84), and those of SARS-CoV (PDB ID: 2DUC), MERS-CoV (PDB ID: 4YLU) and HKU4 (PDB ID: 2YNA), were retrieved from the Protein Data Bank (<http://www.rcsb.org>). All the crystal structures were prepared by removing existing ligands and water molecules, while missing hydrogen atoms were added using Autodock version 4.2 programs (Scripps Research Institute, La Jolla, CA).

### 2.2. Ligand preparation for molecular docking

Structure Data Format of the 173 bioactive phytochemicals derived from *Vernonia amygdalina* and *Occimum gratissimum* were retrieved from the PubChem database ([www.pubchem.ncbi.nlm.nih.gov](http://www.pubchem.ncbi.nlm.nih.gov)) alongside the reference inhibitors viz: Lopinavir, Ritonavir and N-{4-[(1H-benzotriazol-1-ylacetyl) (thiophen-3-ylmethyl)amino]phenyl}propanamide (R30) of 3CL<sup>pro</sup>. They were converted to mol2 chemical format using Open babel [28], while compounds that were not available on the database were drawn with ChemDraw version 19, and converted to mol2 chemical format. Polar hydrogen charges of the Gasteiger-type were assigned to atoms, while the non-polar hydrogen molecules were merged with the carbons. Ligand molecules were further converted to the dockable PDBQT format using AutoDock Tools.









### 2.3. Molecular docking study

An active site targeted molecular docking of the 173 phytochemicals and reference inhibitors against SARS-CoV-2 3CL<sup>pro</sup> was initially performed using AutoDock Vina in PyRx 0.8 [29]. Based on the docking scores, binding poses and interaction in the catalytic site, a hit-list of 21 phytochemicals was defined. The top docked compounds were further docked into the active sites of 3CL<sup>pro</sup> of SARS-CoV, MERS-CoV and HKU4. Before docking analyses, all ligands were imported and energy minimization was performed with OpenBabel [28] incorporated into PyRx 0.8. The Universal Force Field (UFF) was used as the energy minimization parameter and conjugate gradient descent as the optimization algorithm. The grid boxes used for docking studies were obtained by selecting the amino acid residues that define the active site of enzyme and drawing the grid box to enclose them (Table 1). All the other parameters were kept as default. The molecular interactions were viewed with Discovery Studio Visualizer version 16.

### 2.4. Molecular dynamics simulation






The structure of SARS-CoV-2 3CL<sup>pro</sup> was downloaded from the Protein Data Bank with code 6Y84 [30,31]. The unliganded was subjected to a 100 ns production run at the NVT ensemble (normal volume and temperature with a constant number of atoms) molecular dynamics simulation (MDS). Before the production run, the system was subjected

**Table 2**  
Structures of reference inhibitors and top docked phytochemicals with the active sites of 3CL<sup>pro</sup> of Coronaviruses.

S/N	Compounds	Class of compounds	Chemical Structure	Source Plants
S1	Lopinavir			
S2	Ritonavir			
S3	R30			
1	Vernolide	Sesquiterpene lactones		<i>Vernonia amygdalina</i>
2	Vernomygdin	Sesquiterpene lactones		<i>Vernonia amygdalina</i>
3	11, 13-dihydrovernodalin	Sesquiterpene lactones		<i>Vernonia amygdalina</i>
4	Chicoric acid	Phenolic acids		<i>Occinum gratissimum</i>
5	Rosmarinic acid	Phenolic acids		<i>Occinum gratissimum</i>

(continued on next page)

Table 2 (continued)

S/N	Compounds	Class of compounds	Chemical Structure	Source Plants
6	Luteolin	Flavonoids		<i>Occinum gratissimum</i>
7	Neoandrographolide	Diterpenoid lactone		<i>Vernonia amygdalina</i>
8	Vernomenin	Sesquiterpene		<i>Vernonia amygdalina</i>
9	myricetin	Flavonoids		<i>Occinum gratissimum</i>
10	Isorhamnetin	Flavonoids		<i>Vernonia amygdalina</i>

to minimization for 10,000 steps using a conjugate gradient algorithm. CHARMM 36 force field was used in the MDS using the Nanoscale Molecular Dynamics (NAMD 2.13) software [32,33]. Visualizing Molecular Dynamics (VMD 1.9.3) software was used to prepare the input files and analyze the output trajectories [34]. A water box was added to the protein system after adding the missing Hydrogen atoms and removing any ligands. TIP3P water model was used to resemble the added water box, with 10 Å padding, for the periodic boundary condition to be applied [35]. Nose-Hoover Langevin piston was used to control the pressure at 1.01325 bar. In contrast, Langevin dynamics controlled the system's temperature at the physiological value. The temperature, pH, and salt concentration were set at the physiological values (310 K, 7.0, and 0.154 M NaCl, respectively) during the simulation period. The time step was set at its default two fs with SHAKE approximation in action. Subsequently, cluster analysis of the trajectories was performed using the UCSF Chimera software using its default values [36]. A representative conformation from each cluster was used in the in-depth docking experiment as discussed below.

After a series of docking experiments, the backbone protein (3CL<sup>Pro</sup>) and the best two complexes (3CL<sup>Pro</sup>-Neoandrographolide and 3CL<sup>Pro</sup>-

vernolide complexes) were chosen for Molecular Dynamic Simulation (MDS) using NAMD 2.13. The necessary MDS files were generated using CHARMM-GUI [37–39] while setting the salt concentration and temperature to 0.154 NaCl and 310 K, respectively, to mimic the physiological conditions. Before running the production of 50 ns, the system was minimized for 10,000 steps in a constant number of atoms, constant volume, and constant temperature (NVT) ensemble using a conjugate gradient algorithm, then equilibrated in a constant number of atoms, constant pressure, and constant temperature (NPT) ensemble for one ns. The pressure was controlled by the Nose-Hoover Langevin piston set to atmospheric pressure (1.01325 bar), while the temperature was controlled by Langevin dynamics. The force field used was the CHARMM36 force field.

Binding affinity was calculated using Molecular Mechanics Generalized Born Surface Area (MM-GBSA) utilizing MMPBSA.py script implemented in Amber tools 17 [40,41]. All frames (500 frames with time interval of 100 ps between frames) were used in the calculation with salt concentration set to 0.154 Mol, while the rest of the settings were left as default.

**Table 3**

Binding energies of top ten ranked phytochemicals docked in the active sites of 3-Chymotrypsin-like proteases of coronaviruses.

S/ N	Compounds	Binding energies (Kcal/ mol)				
		PubChem ID	SARS- CoV-2	SARS- CoV	MERS- CoV	HKU4
S1	Lopinavir	92,727	-7.2	-8.3		-7.5
S2	Ritonavir	392,622	-7.2	-7.2		-7.1
S3	R30					-7.5
1	Vernolide	5,281,508	-8.0	-7.9	-7.7	-7.7
2	Vernomygdin	-	-7.9	-7.7	-7.6	-7.2
3	11, 13- dihydrovernodalin	23,786,372	-7.8	-7.8	-7.4	-7.2
4	Chicoric acid	5,281,764	-7.7	-7.4	-8.3	-8.9
5	Rosmarinic acid	5,281,792	-7.7	-7.2	-8.0	-8.7
7	Neoandrographolide	9,848,024	-7.7	-8.3	-7.8	-8.1
6	Luteolin	5,280,445	-7.7	-7.7	-7.7	-8.3
8	Vernomenin	442,324	-7.7	-6.9	-6.4	-6.7
9	Myricetin	5,281,672	7.7	-7.5	-7.9	-8.0
10	Isorhamnetin	5,281,654	-7.6	-8.0	-7.7	-8.4

#### 2.4.1. Molecular docking to different clusters from molecular dynamics trajectories

Five different coordinates of 3CL<sup>PRO</sup> after cluster analysis of the MDS trajectories were used to dock the best ten compounds (vernolide, vernomygdin, 11, 13-dihydrovernodalin, neoandrographolide, vernomenin, myricetin, chicoric acid, luteolin, rosmarinic acid, and isorhamnetin) along with the reference inhibitors (ritonavir and lopinavir) using AutoDock Vina software [29,42]. The 3D structures of these ten were generated using the Avogadro software [43], while the Universal Force Field (UFF) was employed to optimize it using the steepest descent algorithm with energies (806, 1046, 2015, 1740, 394, 741, 428, 388, 272, 241, 213, and 875 kJ/mol, respectively) [43–45]. The Protein-Ligand Interaction Profiler (PLIP) web server and PyMOL 2.4 software were utilized to analyze the docking complexes [46].

**Table 4**

Interacting amino acid residues of the 3CL<sup>PRO</sup> of Coronaviruses with the top phytochemicals of *Vernonia amygdalina* and *Occimum gratissimum*.

Compounds	Coronavirus	Residues involved in hydrogen bonding (bond distance, Å)	Residues involved in hydrophobic interactions	Residues involved in others interactions
Lopinavir (S1)	SARS-CoV-2	GLU <sup>166</sup> (2.97) ASN <sup>142</sup> (2.97) PRO <sup>168</sup> (2.97) SER <sup>144</sup> (2.97)	MET <sup>49</sup> HIS <sup>41</sup> LEU <sup>27</sup>	CYS <sup>145</sup>
Ritonavir (S2)		SER <sup>46</sup> (2.46) THR <sup>26</sup> (3.24)	MET <sup>49</sup> MET <sup>165</sup>	GLU <sup>166</sup>
Vernolide		GLY <sup>143</sup> (2.00) MET <sup>165</sup> (3.63) HIS <sup>41</sup> (2.25)	CYS <sup>145</sup>	
Vernomygdin		GLU <sup>166</sup> (2.97) HIS <sup>163</sup> (2.97) ASN <sup>142</sup> (2.97) GLY <sup>143</sup> (2.97) MET <sup>165</sup> (2.97)	CYS <sup>145</sup> LEU <sup>27</sup> MET <sup>4</sup>	
11, 13- dihydrovernodalin		CYS <sup>145</sup> (2.74) ASN <sup>142</sup> (2.25)	MET <sup>165</sup> HIS <sup>41</sup> LEU <sup>27</sup>	
Lopinavir (S1)	SARS-CoV	CYS <sup>145</sup> (2.49) THR <sup>25</sup> (2.74) GLU <sup>166</sup> (2.10, 2.08)	MET <sup>49</sup>	HIS <sup>41</sup>
Ritonavir (S2)		THR <sup>24</sup> (2.31) HR <sup>25</sup> (2.47) THR <sup>26</sup> (2.92) ASN <sup>142</sup> (3.12)	CYS <sup>44</sup> CYS <sup>145</sup> MET <sup>49</sup>	
Neoandrographolide		ASP <sup>48</sup> (2.92) GLU <sup>166</sup> (3.13, 3.37) GLU <sup>47</sup> (2.47)	HIS <sup>41</sup> CYS <sup>145</sup> CYS <sup>44</sup> MET <sup>165</sup>	HIS <sup>163</sup>
Isorhamnetin		HIS <sup>41</sup> (2.47) CYS <sup>145</sup> (2.47) MET <sup>165</sup> (2.47) THR <sup>25</sup> (2.74) MET <sup>49</sup> (2.47) THR <sup>24</sup> (2.74)	MET <sup>49</sup>	GLU <sup>47</sup>
Vernolide		ALA <sup>46</sup> (2.47) THR <sup>26</sup> (2.74) GLY <sup>26</sup> (2.74)	HIS <sup>41</sup> CYS <sup>145</sup>	
Lopinavir	MERS-CoV	GLN <sup>169</sup> (2.81) GLY <sup>167</sup> (2.66)	HIS <sup>41</sup> CYS <sup>145</sup> CYS <sup>44</sup> MET <sup>25</sup>	
R30		GLU <sup>169</sup> (3.42) GLN <sup>167</sup> (3.09)	LEU <sup>49</sup> ALA <sup>46</sup>	
Chicoric acid		GLY <sup>146</sup> (2.36) HIS <sup>166</sup> (2.90, 1.98) SER <sup>147</sup> (2.48) LEU <sup>144</sup> (2.32) THR <sup>193</sup> (1.92) LYS <sup>191</sup> (1.99) GLU <sup>169</sup> (2.70)	CYS <sup>145</sup> MET <sup>168</sup> GLN <sup>192</sup> LEU <sup>170</sup>	
Rosmarinic acid		GLN <sup>167</sup> (2.16) GLU <sup>169</sup> (2.20) GLN <sup>192</sup> (2.68) THR <sup>26</sup> (2.97)	HIS <sup>41</sup> LEU <sup>49</sup>	
Myricetin		PHE <sup>143</sup> (2.40) HIS <sup>166</sup> (2.82) GLU <sup>169</sup> (2.10, 2.14)	CYS <sup>148</sup> LEU <sup>49</sup> HIS <sup>41</sup>	
Ritonavir	HKU4	CYS <sup>145</sup> (3.31) CYS <sup>148</sup> (3.67, 2.75) GLY <sup>167</sup> (2.92, 3.03) GLY <sup>192</sup> (2.06) ASN <sup>122</sup> (2.34)	LEU <sup>49</sup> ALA <sup>46</sup> GLN <sup>169</sup>	HIS <sup>41</sup>
Chicoric acid		CYS <sup>145</sup> (3.68) GLY <sup>146</sup> (2.36) HIS <sup>166</sup> (2.90, 1.98) SER <sup>147</sup> (2.48) LEU <sup>144</sup> (2.32) THR <sup>193</sup> (1.92) LYS <sup>191</sup> (1.99) GLU <sup>169</sup> (2.70)	LEU <sup>49</sup>	
Rosmarinic acid		HIS <sup>41</sup> (3.04) LEU <sup>49</sup> (2.92) TRY <sup>54</sup> (2.68) THR <sup>193</sup> (2.72)	GLY <sup>192</sup> MET <sup>168</sup>	
Isorhamnetin		GLU <sup>169</sup> (2.70) HIS <sup>41</sup> (3.06) LEU <sup>144</sup> (2.70)	MET <sup>168</sup> CYS <sup>145</sup>	

#### 2.5. In silico physicochemical properties and ADMET study


The top ranked compounds based on their binding affinity and docked poses with the 5 different representative structures were subjected to various drug-likeness and ADMET filtering analysis. The drug-likeness analysis which includes Lipinski, Veber, Ghose, Egan and Muegge were performed on the SwissADME (<http://www.swissadme.ch/index.php>) webserver. [47], while the predicted Absorption, Distribution, Metabolism, Excretion and toxicity (ADME/tox) study was analysed using the SuperPred webserver (<http://lmmd.ecust.edu.cn/admetSar1/predict/>) [48]. The SDF file and canonical SMILES of the compounds were downloaded from PubChem Database or copied from ChemDraw to calculate ADMET properties using default parameters.

### 3. Results and discussion

#### 3.1. Screening of phytochemicals against the active site of SARS-CoV-2 3CL<sup>PRO</sup>

Structure-based virtual screening has been used widely to identify potential inhibitors of SARS-CoV-2 replication [16,49]. Common techniques such as molecular docking simulations use scoring functions to estimate the force of non-covalent interactions between a ligand and molecular target in order to predict the best mode of interaction between two molecules to form a stable complex. The preliminary results of molecular docking of the phytochemicals from *Vernonia amygdalina* and *Occimum gratissimum* against the 3CL<sup>PRO</sup> of the novel SARS-CoV-2 alongside with the reference inhibitors (lopinavir and ritonavir) are represented in Table S1 (supplementary material). From the results, a hit list of 21 phytochemicals (Table S2) were selected based on their orientation at the catalytic site, the interacting residues and binding affinities comparable to those of reference inhibitors, lopinavir ( $\Delta G = -7.2$  kcal/mol) and ritonavir ( $\Delta G = -7.2$  kcal/mol).

Further binding docking of the topmost 10 compounds (Table 2) against the active regions of the target protein in SARS-CoV, MERS-CoV and HKU4 (Table 1), revealed that, these chemical structures (Table 2) had considerable docking scores (Table 3) and interactions with the



**Fig. 1.** Amino acid interactions of top binding phytochemicals in the active site of 3-Chymotrypsin-like protease of SARS-CoV-2 3CL<sup>pro</sup>. (S) Surface view (a–e) interactive view. Ligands in stick representation are presented in different colours: (a) green: lopinavir (b) red: ritonavir (c) blue: vernolide (d) orange: vernomygdin (e) purple: 11,13-dihydrovernodalin. Types of interactions are represented by: Green-dotted line-hydrogen bonding; light purple-dotted line-hydrophobic interaction (pi-alkyl, alkyl and pi-stacking); purple-dotted line-pi-pi T-Shaped interaction; light purple-dotted line - pi-stacking interaction yellow-dotted line-pi-sulfur interaction and 3-letter abbreviation of amino acids are in red colour.

coronavirus strains. Early homology models of SARS-CoV-2 3CL<sup>pro</sup> indicated close structural relation to those of other coronaviruses. Superimposition of the X-ray crystal structures of the 3CL<sup>pro</sup> of SARS-CoV-2 and other coronavirus strains indicates a considerable degree of structural similarity and conservation of the active site [8]. This is currently exploited for the development of SARS-CoV-2 3CL<sup>pro</sup> inhibitors that were based on previous compounds targeting the 3CL<sup>pro</sup> of these related coronaviruses [8].

While the top three ranked phytochemicals SARS-CoV-2 3CL<sup>pro</sup> were found to be vernolide, vernomygdin and 11, 13-dihydrovernodalin (−8.0, −7.9 and −7.8 kcal/mol respectively); neoandrographolide, isorhamnetin and vernolide (−8.3, −8.0 and −7.8 kcal/mol respectively) were topmost against SARS-CoV 3CL<sup>pro</sup>; chicoric acid, rosmarinic acid and myricetin (−8.3, −8.0 and −7.9 kcal/mol respectively) against MERS-CoV and chicoric acid, rosmarinic acid and isorhamnetin (−8.9, −8.7 and −8.4 kcal/mol respectively) against HKU4 (Table 3). It was observed that the top three ranked phytochemicals for SARS-CoV-2 and SAR-CoV 3CL<sup>pro</sup>s were isolated from *Vernonia amygdalina* while those for HKU4 3CL<sup>pro</sup> were from *Occimum gratissimum*.

### 3.2. Molecular interactions between the top docking phytochemicals and the active sites of 3CL<sup>pro</sup> of coronaviruses


A monomer of 3CL<sup>pro</sup> is made up of three domains: domain I (residues 8–101), domain II (residues 102–184), and domain III (residues 201–303) and a long loop (residues 185–200) connects domains II and III. Domains I and II comprise six-stranded antiparallel β-barrels with the substrate binding site at the intersection of the two domains. The enzymatic activity of 3CL<sup>pro</sup> resides in the catalytic dyad of Cys<sup>145</sup> and His<sup>41</sup> [50]. The substrate-binding pocket lies in the cleft between domains I and II, and features the catalytic dyad residues Cys<sup>145</sup> and His<sup>41</sup>. The substrate-binding pocket is divided into a series of subsites (including S1, S2, S4 and S1'), each accommodating a single but consecutive amino acid residue in the substrate. Ser<sup>1</sup> in each one monomer interacts with Phe<sup>140</sup> and Glu<sup>166</sup> of the other monomer to stabilize the S1 subsite, a structural feature that is essential for catalysis [51]. The current study revealed that, the reference drugs and the top-docking phytocompounds form complexes with SARS-CoV-2 3CL<sup>pro</sup> that are stabilized by numerous non-covalent interactions in the active regions of the target protein of the coronaviruses as shown in Table 4.

Lopinavir and ritonavir the antiretroviral protease inhibitors which were originally developed for use against HIV and later recommended for the treatment of SARS and MERS infections [52], were used as reference drugs. The interactions of lopinavir were majorly through hydrogen bonds and hydrophobic interactions, with few electrostatic interactions. While the 4-hydroxyl and acetyl group of lopinavir interacted via hydrogen bond with GLU<sup>166</sup> and SER<sup>144</sup> of the domains I and II of 3CL<sup>pro</sup> of SARS-CoV-2, its 3-methyl and 1-phenyl moieties interacted via a hydrogen bonds. The 1-phenyl and the methyl moieties of the 2, 6-dimethylphenoxy interacted via hydrophobic interactions with the catalytic dyad (Cys<sup>145</sup> and His<sup>41</sup>) residues of 3CL<sup>pro</sup> of SARS-CoV-2 (Fig. 1). For 3CL<sup>pro</sup> of SARS-CoV, the 1-amino group of 2-oxo-1,3-diazinan-1-yl, 4-hydroxyl and acetyl groups of lopinavir interacted via H-bond with GLU<sup>166</sup>, THR<sup>25</sup> and CYS<sup>145</sup> in the same domain as SARS-CoV-2 while the 3-methyl and 1-phenyl groups formed an alkyl and pi-sulfur interaction with MET<sup>49</sup> and CYS<sup>145</sup> respectively (Figure S1). In the case of HKU4, two hydrogen bonds were observed between GLU<sup>169</sup> and GLN<sup>167</sup> and the carbonyl group and amino group of the butanamide moiety of lopinavir respectively (Figure S2), while hydrophobic interactions were formed by the phenyl rings. In the same vein, ritonavir having the same binding affinities as lopinavir interacted in a different manner with 3CL<sup>pro</sup> of the coronaviruses. The 15-hydroxy, 7-oxatetracyclo moiety and the carbonyl group of methylprop-2-enoate of vernolide interacted via H-bond with HIS<sup>41</sup>, GLY<sup>143</sup> and MET<sup>165</sup> of 3CL<sup>pro</sup> of SARS-CoV-2, while the heptadec-9-en-3-yl ring formed an alkyl interaction with CYS<sup>145</sup> (Table 4). The hydrogen bonds observed

between vernomygdin and HIS<sup>163</sup>, GLU<sup>166</sup>, and GLY<sup>143</sup> of 3CL<sup>pro</sup> of SARS-CoV-2 were contributed by dihydrofuran-2 (3H)-one and the carbonyl group of methylpropanoate. The heptadec-9-en-3-yl ring and the alkyl group of methylpropanoate moiety were responsible for the alkyl interactions with amino acids of 3CL<sup>pro</sup> of SARS-CoV-2. The hydroxyl group of hydroxymethyl-prop-2-enoate of 11, 13-dihydrovernodalin contributed the only hydrogen bonds with CYS<sup>145</sup> of 3CL<sup>pro</sup> of SARS-CoV-2. Several alkyl and pi-alkyl interactions were formed by the rings and methyl group of the furan ring of 11, 13-dihydrovernodalin and 3CL<sup>pro</sup> of SARS-CoV-2.

Vernolide, vernomygdin and 11, 13-dihydrovernodalin, the best docked phytochemicals in the SARS-CoV-2 3CL<sup>pro</sup> were observed to interact with the S1 subsite residues such as HIS<sup>41</sup>, ASN<sup>142</sup>, GLY<sup>143</sup>, SER<sup>144</sup> and the GLU<sup>166</sup> of β11. Interactions with the S1 and β11 residues have been reported for some other inhibitors of SARS-CoV-2 replication [6,51], suggesting that these three phytochemicals may effectively inhibit the proliferation of the virus. Interactions of the compounds at the S2 subsite were predominantly hydrophobic except for vernomygdin that formed a hydrogen bond with HIS<sup>163</sup> and important residue in the hydrophobic pack that have been implicated in its catalytic activity [6] (Table 4). The binding of the top three ranked compounds docked in 3CL<sup>pro</sup> of the coronaviruses revealed that isorhamnetin and all the phytochemicals of *V. amygdalina* interacted with both amino acids of the catalytic dyad, indicating that they may be more effective inhibitors of the enzyme. The stability of the complexes formed stemmed from the vast number of interactions with some important active site residues HIS<sup>41</sup>, MET<sup>49</sup>, MET<sup>165</sup>, THR<sup>25</sup>, LEU<sup>27</sup>, ASP<sup>48</sup>, LEU<sup>50</sup>, LEU<sup>141</sup>, CYS<sup>145</sup>, HIS<sup>164</sup>, LEU<sup>167</sup>, PRO<sup>168</sup>, AEP<sup>187</sup>, and ALA<sup>191</sup> which have been reported to be significant for the binding of the inhibitors with 3CL<sup>pro</sup> [53]. SARS-CoV 3CL<sup>pro</sup> had the highest binding affinity for neoandrographolide, a diterpene lactone obtained from *V. amygdalina*. The 2H-Furan-5-one ring formed two hydrogen bonds to ASP<sup>48</sup> and GLU<sup>47</sup>. An alkyl interaction was formed by the methyl group at the oxan-2-yl-oxymethyl junction with CYS<sup>145</sup> while the several pi-alkyl interactions were majorly formed by the 1H-naphthalen-1-yl and 2H-Furan-5-one ring (Figure S1). Isorhamnetin, an O-methylated flavonol obtained from *Vernonia amygdalina* interacted via conventional H-bonds with GLU<sup>166</sup>, GLY<sup>143</sup> and THR<sup>45</sup>. A carbon hydrogen interaction was observed with CYS<sup>145</sup> and THR<sup>24</sup>, while pi-cation, pi-sulfur and pi-alkyl were observed between the rings and HIS<sup>45</sup>, MET<sup>49</sup> and CYS<sup>145</sup> respectively. The carbonyl group of methylprop-2-enoate moiety and 15-hydroxyl group of vernolide formed a conventional hydrogen bond with GLY<sup>143</sup> and THR<sup>25</sup> of SARS-CoV 3CL<sup>pro</sup>. Pi-alkyl and alkyl interactions of the heptadec-9-en-3-yl with HIS<sup>41</sup> and CYS<sup>145</sup> were also observed. Phytocompounds from the plants had comparable interactions with MERS-CoV as the co-crystallized compound N-{4-[(1H-benzotriazol-1-yl)acetyl] (thiophen-3-ylmethyl)amino}phenyl}propanamide (Tables 3 and 4). Chicoric acid and rosmarinic acid, from *Occimum gratissimum*, were the top docked phytochemicals to MERS-CoV and HKU4 3CL<sup>pro</sup>. The 3,4-hydroxyl group on the two phenyl moiety of chicoric acid were major donors of hydrogen atoms for the H-bonds, while the first phenyl ring made Pi-sulfur and Pi-alkyl contacts to the active site cysteine (CYS<sup>148</sup> and CYS<sup>145</sup>) of MERS-CoV. The hydroxyl and the carbonyl group of the prop-2-enoyl moiety of rosmarinic acid formed hydrogen bonds to GLN<sup>167</sup> and GLU<sup>169</sup> respectively. The phenyl ring linked to the prop-2-enoyl group formed Pi-Pi T-shaped and Pi-Alkyl contact to HIS<sup>41</sup> and LEU<sup>49</sup> of MERS-CoV respectively (Figure S2). The 3 hydroxyl unit attached to ring B of myricetin formed 2 hydrogen bonds with PHE<sup>143</sup> and GLU<sup>169</sup>, while the 4-hydroxyl formed a hydrogen bond with HIS<sup>166</sup>. The A and C rings of myricetin made Pi-Pi-stacked contacts with HIS<sup>41</sup>, while the B ring made Pi-Alkyl and Pi-sulfur contacts with LEU<sup>49</sup> and CYS<sup>148</sup> (Figure S2). In the case of HKU4, the hydroxyl and carbonyl groups on prop-2-enoyl [oxy]butanedioic moiety of chicoric acid interacted via several H-bonds with the residues at the active site. The hydroxyl and carbonyl groups on prop-2-enoyl [oxy]propanoic moiety of rosmarinic acid contributed the 3 hydrogen bonds to TYR<sup>54</sup>,





**Fig. 2.** The average binding energy values of the reference compounds (Ritonavir and Lopinavir) and the best ten natural compounds calculated with AutoDock Vina software.

**Table 5**

The interactions of the top 10 ranked phytochemicals of *Vernonia amygdalina* and *Ocimum gratissimum* and positive control (Ritonavir and Lopinavir) for the best representative conformation from the cluster analysis of SARS-CoV-2 3CL<sup>Pro</sup> molecular dynamics simulation (MDS) trajectories.

Compound	Binding energies (kcal/mol)	H-bonding		Hydrophobic interactions	
		Number	Residues from SARS-CoV-2 3CL <sup>Pro</sup>	Number	Residues from SARS-CoV-2 3CL <sup>Pro</sup>
Ritonavir	-6.4	6	<b>ASN<sup>142</sup>(2), GLY<sup>143</sup>, SER<sup>144</sup>, CYS<sup>145</sup>, and GLU<sup>166</sup></b>	1	MET <sup>165</sup>
Lopinavir	-6.3	5	<b>ASN<sup>142</sup>, GLY<sup>143</sup>, ASP<sup>178</sup>(2), and GLN<sup>189</sup></b>	1	THR <sup>25</sup>
Vernolide	-7.5	3	<b>GLY<sup>143</sup>, SER<sup>144</sup>, and CYS<sup>145</sup></b>	1	MET <sup>165</sup>
Vernomygdin	-6.9	5	<b>ASN<sup>142</sup>, GLY<sup>143</sup>, SER<sup>144</sup>, CYS<sup>145</sup>, and GLN<sup>189</sup></b>	2	MET <sup>165</sup> , and GLU <sup>166</sup>
11, 13-dihydrovernodalin	-6.6	6	<b>ASN<sup>28</sup>(2), GLY<sup>143</sup>, SER<sup>144</sup>, CYS<sup>145</sup>, and GLU<sup>166</sup></b>	3	LEU <sup>27</sup> (2), and MET <sup>165</sup>
Neoandrographolide	-7.7	7	<b>THR<sup>45</sup>, SER<sup>46</sup>, LEU<sup>50</sup>, ASN<sup>142</sup>, GLY<sup>143</sup>, SER<sup>144</sup>, and CYS<sup>145</sup></b>	1	THR <sup>25</sup>
Vernomenin	-6.4	3	<b>GLY<sup>143</sup>, SER<sup>144</sup>, and CYS<sup>145</sup></b>	2	THR <sup>25</sup> , and LEU <sup>27</sup>
Myricetin	-7.1	7	<b>LEU<sup>141</sup>, ASN<sup>142</sup>, GLY<sup>143</sup>, SER<sup>144</sup> (3), and GLU<sup>166</sup></b>	0	
Chicoric acid	-7.3	6	<b>LEU<sup>141</sup>, ASN<sup>142</sup>, GLY<sup>143</sup>, SER<sup>144</sup> (2), and CYS<sup>145</sup></b>	1	GLN <sup>189</sup>
Luteolin	-7.2	4	<b>SER<sup>144</sup>, GLU<sup>166</sup>(2), and GLN<sup>189</sup></b>	0	
Rosmarinic acid	-6.8	7	<b>THR<sup>26</sup> (2), PHE<sup>140</sup>, LEU<sup>141</sup>, GLY<sup>143</sup>, SER<sup>144</sup>, and CYS<sup>145</sup></b>	0	
Isohammetin	-7.4	6	<b>ASN<sup>142</sup>, GLY<sup>143</sup>, SER<sup>144</sup> (3), and CYS<sup>145</sup></b>	0	

Residues in bold represent the most reported residues that interacted with the compounds.


LEU<sup>49</sup> and HIS<sup>41</sup> (Figure S3), while the first 3,4-dihydroxyphenyl moiety formed the hydrophobic interactions. HIS<sup>41</sup> formed both hydrogen bond and pi-pi T-shaped interaction with the carbonyl group on the chromen-4-one moiety of isorhammetin. The 4-hydroxy-3-methoxyphenyl moiety of isorhammetin formed carbon hydrogen and pi-alkyl interactions with CYS<sup>145</sup> (Figure S3).

### 3.3. Optimization of docking interactions of phytochemicals with SARS-CoV-2 3CL<sup>Pro</sup> conformations

An in-depth docking simulation of the phytochemicals and reference inhibitors was performed to optimize the docking experiment and interactions with the target protein using previously reported protocols [54,55]. Fig. 2 shows the average binding affinities of the best ten phytochemicals along with the reference inhibitors (positive controls) against the five different representative conformations gotten from the clustering analysis of the SARS-CoV-2 3CL<sup>Pro</sup> MDS trajectories (see Figure S3). The means and the standard errors of the mean of the 5 binding energies for each representative conformation of SARS-CoV-2 3CL<sup>Pro</sup> were calculated for each phytochemicals and reference inhibitors. As reflected from the binding energy values, the ten phytochemicals are able to bind effectively to the SARS-CoV-2 3CL<sup>Pro</sup> different conformations, just like the positive controls. The binding energy values

ranged from -6.1 Kal/mol (rosmarinic acid) down to -8.1 kcal/mol (neoandrographolide and chicoric acid). As reflected from Fig. 2, vernolide, neoandrographolide, myricetin, chicoric acid, luteolin, and Isohammetin (green columns) are the compounds with best the binding affinities to SARS-CoV-2 3CL<sup>Pro</sup>. The interactions of the best docked phytochemicals with SARS-CoV-2 3CL<sup>Pro</sup> were further analysed using the PLIP webserver.

From the docking results, five complexes for each phytochemical were generated. The best representative complex for each phytochemical was selected based on the binding affinity for further analysis using the PLIP webserver. The details of the interactions established upon docking of the reference inhibitors and the best ten phytochemicals against SARS-CoV-2 3CL<sup>Pro</sup> are presented in Table 5. The most reported types of interactions are hydrogen bonding and few hydrophobic contacts in some complexes. At least three hydrogen bond, and up to seven were reported in the docking complexes between the compounds and SARS-CoV-2 3CL<sup>Pro</sup>. The most-reported residues from the 3CL<sup>Pro</sup> that interacted with the ligands (represented in bold in Table 5) are ASN<sup>142</sup>, GLY<sup>143</sup>, SER<sup>144</sup>, CYS<sup>145</sup>, and GLU<sup>166</sup>, and these formed 6, 9, 14, 7, and 5 interactions with the ligands, respectively. CYS<sup>145</sup> is one of the 3CL<sup>Pro</sup> active site dyads (HIS<sup>41</sup> and CYS<sup>145</sup>), and it was reported in all the ligands except myricetin and luteolin. So far, two terpenoid structures viz: vernolide and neoandrographolide with strong interactions with the



**Fig. 3.** The interaction pattern of the best six phytochemical structures with the active site of the best representative conformation from the cluster analysis of SARS-CoV-2 3CL<sup>Pro</sup> MDS trajectories. The residues of the 3CL<sup>Pro</sup> are shown in blue sticks labelled by its one-letter code. The ligands are represented in yellow sticks with cyan aromatic rings. H-bonds are shown in blue lines while hydrophobic contacts in dashed-gray lines.

active region of SARS-CoV-2 3CL<sup>Pro</sup> have been identified (Fig. 2, Table 5 and Fig. 3). The surface views of these structures in the substrate binding pocket of SARS-CoV-2 3CL<sup>Pro</sup> are shown in Fig. 4.

Binding interactions of neoandrographolide at the enzyme catalytic site is stabilized by several H bonds between its 2H-Furan-5-one ring and key residues (ASN<sup>142</sup>, GLY<sup>143</sup>, SER<sup>144</sup>, CYS<sup>145</sup>) of catalytic pocket of the enzyme, which led this ring to be sandwiched between CYS<sup>145</sup> and ASN<sup>142</sup> (Fig. 3). Furthermore, neoandrographolide structure inserts into the bulky hydrophobic S1/S2 subsites (composed of the side chains of HIS<sup>41</sup>, MET<sup>49</sup>, HIS<sup>41</sup>, ASN<sup>142</sup>, GLY<sup>143</sup>, SER<sup>144</sup>, and MET<sup>165</sup>) (Figs. 3 and 4b). Consequently, neoandrographolide was accommodated in the substrate-binding pocket and interacted with the catalytic residues, the oxyanion loop (residues 138–145), and the S1/S2 subsites, which are the key elements for the recognition of substrates. Interactions with the S1 have been reported for some other inhibitors of SARS-CoV-2 replication

[6,51] suggesting that this structure may effectively inhibit the proliferation of the virus. With the aid of an array of direct and indirect hydrogen bonds with ASN<sup>142</sup>/GLY<sup>143</sup>/SER<sup>144</sup>/CYS<sup>145</sup>, neoandrographolide may fix the conformation of the flexible oxyanion loop, which served to stabilize the tetrahedral transition state of the proteolytic reaction. This binding mode of neoandrographolide is similar in many respect to that of baicalein, the first natural noncovalent, non-peptidomimetic inhibitor of SARS-CoV-2 3CL<sup>Pro</sup> derived from Shuangguanglian [56]. Vernolide, another terpenoid structure (sesquiterpene lactone) isolated from *Vernonia amygdalina* is a potential non-covalent inhibitor of SARS-CoV-2 3CL<sup>Pro</sup> inhibitor. Its interactions with the active site of this enzyme mimic the non-covalent interactions of carmofur, a potent covalent inhibitor of this enzyme which also establishes non-covalent interactions with its target [57]. The carbonyl group of methylprop-2-enoate moiety of vernolide occupies the oxyanion hole




Fig. 4. Surface representation of (a) vernolide and (b) neoandrographolide in the substrate-binding pocket of SAR-CoV-2 3CL<sup>Pro</sup>.

and forms hydrogen bonds with the backbone amides of Gly<sup>143</sup>, and Cys<sup>145</sup> (Figs. 3 and 4a), mimicking the tetrahedral oxyanion intermediate formed during protease cleavage. A side chain of vernolide inserts into the bulky hydrophobic S2 subsite (composed of the side chains of HIS<sup>41</sup> and MET<sup>165</sup>) (Figs. 3 and 4a). Therefore, these terpenoid structures alongside other phytochemicals from the source plants may be suggested as inhibitors of SARS-CoV-2 3CL<sup>Pro</sup>.

### 3.4. *In silico* drug-likeness and pharmacokinetic properties of topmost phytochemicals

The top 6 phytochemicals (Neoandrographolide, vernolide, isorhamnetin, chicoric acid, luteolin, and Myricetin) from the docking analysis to the representative conformation gotten from the clustered MDS trajectories were subjected to the predictive pharmacokinetics drug-likeness and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) filtering analyses. The result of the analyses for the six-top phytochemicals is represented in Table 6. Several pharmacokinetic and ADMET molecular descriptors were used for the assessment (Table 6). From these six, four phytochemicals (vernolide, neoandrographolide, isorhamnetin and luteolin), fulfilled the requirement for at least four from the five physicochemical analyses (Lipinski, Veber, Ghose, Egan and Muegge). Five of the compounds except chicoric acid having 2 violations of greater than 5 H-bond donors and 10 H-bond acceptors atoms from Lipinski filter and a higher number of rotatable bonds above 10 and TPSA greater than 140 for the Veber filter. The five compounds are predicted to have good absorption or permeation from Lipinski filters [58] and good oral bioavailability from Veber filters [59]. The Ghose's filter that is based on computed physicochemical property profiles such as log P, molar refractivity, molecular weight, number of atoms as well of functional groups [60] screened out neoandrographolide and myricetin with two and one violations respectively. The Egan's and Muegge's filters screened out chicoric acid and

myricetin. The Egan's filter is based on the physical processes involved in membrane permeability [61] while the Muegge's filter is based on the underfunctionalized properties of nondrug compounds [59]. Vernolide, neoandrographolide, isorhamnetin and luteolin also presented good Abbot Bioavailability Score [62] that is based on their predominant charges at biological pH. The molecular properties of the four phytochemicals based on the severally computed partition coefficient (log P) showed that the drugs had relatively good lipophilicity with logP values were less than 5 [63].

The Caco-2 permeability and intestinal absorption (HIA) descriptors determine the ultimate bioavailability of the drug. Compounds with low Caco-2 permeability potential ( $<8 \times 10^{-6}$  cm/s) could be absorbed through the human intestinal wall [64]. The permeability glycoprotein (P-gp) is expressed in the intestinal epithelium, kidney cells liver cells, blood-brain barrier and blood-testis barrier capillary endothelial cells, where it functions by pumping xenobiotics back into the intestinal lumen, urine-conducting ducts bile ducts, and capillaries [65]. Vernolide and luteolin, expressed positive and high probability of human intestinal absorption and non-substrate to the permeability-glycoprotein (P-gp), while the all the six phytochemicals presented positive Caco-2 permeability. It is thereby suggested that vernolide will be absorbed into the blood stream subverting the capability of P-gp to pumps them back into the intestinal lumen, bile ducts, urine-conducting ducts and capillaries [65]. Blood brain barrier (BBB) penetration, predicts the blood brain barrier penetration of a molecule. Vernolide displayed properties that indicated their ability to cross the BBB. SARS-CoV-2 has been reported to infect the brain, thus indicating its ability to cross the blood brain barrier (BBB) [66], compounds that can cross the BBB will be beneficial in the overall viral clearance. compounds that can cross the BBB will be beneficial in the overall viral clearance. The estimated half-life time (less than 2 h) and clearance ratefall within the moderate range. Vernolide, neoandrographolide, isorhamnetin presented a tolerable LD<sub>50</sub> between (51–500 mg/kg), Among the descriptors for the *in*

Table 6

In silico Physicochemical and ADMET<sup>a</sup> parameters of the top-binding phytochemicals of *Vernonia amygdalina* and *Occinum gratissimum* with 3CL<sup>PRO</sup> of SARS-CoV-2.


a) Physicochemical properties	Vernolide	Neoandrographolide	Isorhamnetin	Chicoric acid	Luteolin	Myricetin
Molecular weight (g/mol)	362.37	480.59	316.26	474.37	286.23	318.24
Num. heavy atoms	26	34	23	34	21	23
Num. arom. Heavy atoms	0	0	16	12	16	16
Num. rotatable bonds	3	7	2	11	1	1
Num. H-bond acceptors	7	8	7	12	6	8
Hydrogen bond donor	1	4	4	6	4	6
iLogP	2.45	3.27	2.35	1.00	1.86	1.08
XLogP	0.93	2.63	1.87	2.01	2.53	1.18
WLogP	1.17	1.83	2.29	1.01	2.28	1.69
MLogP	1.18	1.26	-0.31	0.14	-0.03	-1.08
Molar Refractivity	89.51	125.27	82.50	114.00	76.01	80.06
TPSA (Å <sup>2</sup> )	94.59	125.68	120.36	208.12	111.13	151.59
<b>Drug-likeness</b>						
Lipinski	Yes	Yes	Yes	No (2 violations: <i>NorO</i> >10, <i>NHorOH</i> >5)	Yes	Yes
Veber	Yes	Yes	Yes	No (2 violations: <i>Rotors</i> >10, <i>TPSA</i> >140)	Yes	Yes
Ghose	Yes	No (2 violations: <i>MW</i> >480, <i>No. of atoms</i> >70)	Yes	Yes	Yes	No (1 violation: <i>TPSA</i> >140)
Egan	Yes	Yes	Yes	No(1 violation: <i>TPSA</i> >131.6)	Yes	No (1 violation: <i>TPSA</i> >131.6)
Muegge	Yes	Yes	Yes	No (3 violations: <i>TPSA</i> >150, <i>H-acc</i> >10, <i>H-don</i> >5)	Yes	No (2 violations: <i>TPSA</i> >150, <i>H-don</i> >5)
Bioavailability Score	0.55	0.55	0.55	0.11	0.55	0.55
<b>Absorption (Probability)</b>						
<b>(b) Admet SAR</b>						
HIA	HIA+ (0.58)	HIA- (0.127)	HIA- (0.498)	HIA+ (0.883)	HIA+ (0.9650)	HIA- (0.437)
Caco-2 Permeability Cm/s	Caco2+ (-5.096)	Caco2+ (-5.84)	Caco2+ (-5.217)	Caco2+ (-6.709)	Caco2+ (-5.12)	Caco2+ (-6.63)
P-glycoprotein Substrate	Neg. (0.484)	Pos. (0.778)	Neg. (0.015)	Neg. (0.051)	Neg. (0.038)	Neg. (0.208)
P-glycoprotein Inhibitor	Neg. (0.027)	Neg. (0.007)	Pos. (0.538)	Neg. (0.193)	Neg. (0.366)	Neg. (0.064)
<b>Distribution (Probability)</b>						
Blood-Brain Barrier	BBB+ (0.4.39)	BBB- (0.476)	BBB- (0.34)	BBB+ (0.552)	BBB-(0.464)	BBB- (0.4.27)
PPB %	65.501	72.039	90.707	76.782	91.796	76.595
VD L/kg	-0.147	-0.452	-0.932	-1.406	-1.406	-1.39
<b>Metabolism (Probability)</b>						
CYP450 1A2 Inhibitor	Neg. (0.069)	Neg. (0.028)	Pos. (0.941)	Neg. (0.239)	Neg. (0.069)	Neg. (0.133)
CYP450 1A2 Substrate	Neg. (0.33)	Neg. (0.258)	Neg. (0.456)	Neg. (0.262)	Pos. (0.968)	Pos. (0.968)
CYP450 3A4 Inhibitor	Neg. (0.149)	Neg. (0.262)	Pos. (0.768)	Neg. (0.087)	Neg. (0.412)	Neg. (0.376)
CYP450 3A4 Substrate	Neg. (0.562)	Neg. (0.523)	Neg. (0.428)	Neg. (0.15)	Pos. (0.867)	Neg. (0.459)
CYP4502C9 Inhibitor	Neg. (0.116)	Neg. (0.144)	Neg. (0.183)	Neg. (0.071)	Neg. (0.328)	Pos. (0.656)
CYP450 2C9 Substrate	Neg. (0.313)	Neg. (0.408)	Pos. (0.772)	Pos. (0.504)	Neg. (0.0496)	Pos. (0.557)
CYP4502C19 Inhibitor	Neg. (0.093)	Neg. (0.103)	Neg. (0.24)	Neg. (0.157)	Neg. (0.124)	Neg. (0.068)
CYP450 2C19 Substrate	Neg. (0.474)	Neg. (0.462)	Pos. (0.54)	Neg. (0.334)	Pos. (0.542)	Neg. (0.345)
CYP4502D6 Inhibitor	Neg. (0.296)	Neg. (0.329)	Neg. (0.468)	Neg. (0.248)	Neg. (0.463)	Neg. (0.318)
CYP450 2D6 Substrate	Neg. (0.267)	Neg. (0.274)	Neg. (0.41)	Neg. (0.415)	Neg. (0.401)	Neg. (0.18)
<b>Elimination</b>						
T <sub>1/2</sub> (Half Life Time)	0.883 h	1.53 h	0.658 h	1.79 h	0.745 h	1.915 h
CL (Clearance Rate) mL/min/kg	1.914	1.032	1.951	0.823	1.919	1.709
<b>Toxicity</b>						
hERG Blockers	Ng. (0.256)	Neg. (0.474)	Neg. (0.301)	Neg. (0.578)	Neg. (0.436)	Neg. (0.353)
H-HT	Neg. (0.444)	Pos. (0.584)	Pos. (0.654)	Neg. (0.348)	Pos. (0.592)	Neg. (0.332)
AMES	Neg. (0.411)	Neg. (0.224)	Neg. (0.044)	Neg. (0.224)	Pos (0.74)	Neg. (0.074)
SkinSen	Neg (0.340)	Neg (0.256)	Neg (0.186)	Neg (0.414)	Neg (0.278)	Neg. (0.278)
LD <sub>50</sub> (LD <sub>50</sub> of acute toxicity)	3.211 -log mol/kg (222.927 mg/kg)	3.448-log mol/kg (171.31 mg/kg)	2.71-logmol/kg (604.02mg/kg)	2.38-logmol/kg (1945.92mg/kg)	2.58 -log mol/kg (737.444 mg/kg)	2.69 -log mol/kg (648.262 mg/kg)
DILI	Neg. 0.424	Neg. (0.196)	Pos. 0.904	Pos. 0.84	Pos. 0.9	Pos. 0.9
<b>Pharmacokinetics</b>						
GI absorption	High	High	High	High	High	High
Log K <sub>p</sub> (skin permeation) cm/s	-7.85	-7.36	-6.93	-7.77	-6.25	-7.40

<sup>a</sup> ADMET: Absorption, distribution, metabolism, elimination, and toxicity; GI: Gastro-intestinal; BBB: Blood Brain Barrier; P-gp: permeability glycoprotein; CYP: cytochrome P450; hERG: human Ether-à-go-go-Related Gene; HIA: Human Intestinal Absorption; H-HT: Human Hepatotoxicity AMES: Ames Mutagenicity; DILI: Drug Induced Liver Injury; VD: Volume Distribution; PPB: Plasma Protein Binding.

**Table 7**

The MM-GBSA calculations for the best two complexes after 50 ns MDS. Red coloured residues represent the residue have negative contribution on the binding (positive binding energies). The average binding free energies and its individual terms are shown at the bottom for each complex with its standard deviations.

COMPLEX	3CL <sup>PRO</sup> -Ritonavir complex		3CL <sup>PRO</sup> - Neoandrographolide complex		3CL <sup>PRO</sup> -vernalide complex	
	Residue	Binding energy (kcal/mol)	Residue	Binding energy (kcal/mol)	Residue	Binding energy (kcal/mol)
RESIDUAL CONTRIBUTION TO BINDING	Y118	-1.32	C44	-0.60	M165	-1.22
	L141	-0.91	L50	-0.38	<u>H41</u>	<u>-1.16</u>
	N142	-0.86	P52	-0.36	<u>C145</u>	<u>-1.00</u>
	N119	-0.80	Q189	-0.34	H164	-0.91
	G143	-0.59	N51	-0.25	L27	-0.88
	E14	-0.35	R188	-0.21	Q189	-0.41
	G124	-0.28	S46	-0.20	T25	-0.29
	L27	-0.27	T21	-0.14	V42	-0.20
	V125	-0.23	<u>C145</u>	<u>-0.13</u>	P39	-0.19
	T26	-0.20	T25	-0.13	R40	-0.18
	P122	-0.13	T26	-0.13	C44	-0.18
	M6	-0.12	R40	-0.13	V186	-0.17
	S144	-0.11	T24	-0.11	G143	-0.09
	A7	-0.10	T45	-0.11	C38	-0.07
	A116	-0.10	Q19	-0.10	I43	-0.07
	F140	-0.10	G143	-0.08	<b>E166</b>	<b>+0.27</b>
			L141	-0.07		
		<b>D187</b>	<b>+0.22</b>			
$\Delta E_{VDW}$ (kcal/mol)	-21.58 ±8.7	-16.27 ±9.9	-25.1 ±2.2			
$\Delta E_{ELE}$ (kcal/mol)	-137.99 ±33.3	-8.24 ±8.7	-5.45 ±3.3			
$\Delta G_{GB}$ (kcal/mol)	150.78 ±33.7	20.3 ±13.0	19.34 ±3.2			
$\Delta G_{SA}$ (kcal/mol)	-3.14 ±1.2	-2.47 ±1.5	-3.37 ±0.3			
$\Delta G_{GAS}$ (kcal/mol)	-159.56 ±37.4	-24.50 ±16.4	-30.54 ±4.0			
$\Delta G_{SOLV}$ (kcal/mol)	147.64 ±32.9	17.83 ±11.8	15.97 ±3.1			
<b><math>\Delta G_{TOTAL}</math></b> (kcal/mol)	<b>-11.92</b> ±6.0	<b>-6.68</b> ±5.9	<b>-14.57</b> ±2.2			



**Fig. 5.** A) The Root Mean Square Deviation (RMSD) and the Radius of Gyration (RoG) versus the simulation time in nanoseconds for the 3CL<sup>PRO</sup>-Ritonavir (blue line), 3CL<sup>PRO</sup>-Neoandrographolide (orange line), and 3CL<sup>PRO</sup>-Vernolide (gray line). B) The per-residue RMSF calculated for the apo-protein (blue), 3CL<sup>PRO</sup>-Neoandrographolide (red), and 3CL<sup>PRO</sup>-Vernolide (green). The structure of the protein is represented in a green cartoon with some residues in coloured sticks. C) An enlarged panel of the RMSF curves at the S46–P52 region for the three complexes and the apo form of 3CL<sup>PRO</sup>.

*in silico* toxicities analysis, hERG channel plays a vital role in the repolarization and termination stages of action potential in cardiac cells [67]. Compounds that block the hERG channel have the potential to cause cardiotoxicity [68]. All the six phytochemicals did not exhibit the potential of being hERG channel blockers, suggesting that they may not cause hERG channel-related cardiotoxicity [68]. The three compounds did not exhibit mutagenicity *in silico*, thereby they may not cause genetic mutations, which do initiate the pathophysiology of other diseases, such as cancer [69]. The impact of the compounds on phase I drug metabolism in the liver was also analysed using the various cytochrome P450 descriptors. Vernolide, neoandrographolide did not display inhibitory potential for the various cytochrome P450, thus may not adversely affect phase I drug metabolism in the liver. Hence, vernolide, neoandrographolide seem to demonstrate high probability of absorption, subcellular distribution, and low toxicity.

### 3.5. Molecular dynamic simulations and binding free energy calculation for the best two complexes and the reference complex

MDS for the best two complexes in addition to the 3CL<sup>PRO</sup>-ritonavir were performed for 50 ns using NAMD software, and then the MM-GBSA was done using Amber tools. In Table 7, the residual contribution for the binding of 3CL<sup>PRO</sup> against the best two compounds (Neoandrographolide and Vernolide) and the reference compound (ritonavir) are listed with the bold residues for the highest contributed residues in the binding (bold). The active site dyads (H<sup>41</sup> and C<sup>145</sup>) are shown underlined in the table as well. For the 3CL<sup>PRO</sup>-Neoandrographolide complex, C<sup>44</sup> is the main contributor for the binding (−0.60 kcal/mol), while for the 3CL<sup>PRO</sup>-Vernolide complex, H<sup>41</sup>, C<sup>145</sup>, and M<sup>165</sup> are the main contributors (−1.16, −1.00, and −1.22 kcal/mol, respectively). The contribution of the active site dyads (H<sup>41</sup> and C<sup>145</sup>) of the 3CL<sup>PRO</sup> in the binding of Vernolide to the protein is evident from Table 7 (−2.16 kcal/mol). In comparison, a lower contribution of these two residues was reported in the case of the 3CL<sup>PRO</sup>-Neoandrographolide and 3CL<sup>PRO</sup>-Ritonavir complexes (−0.13 and −0.04 kcal/mol, respectively). The D<sup>187</sup> and E<sup>166</sup> (red coloured) have negative contribution to the binding of the 3CL<sup>PRO</sup> to Neoandrographolide and Vernolide, respectively (+0.22 and + 0.27 kcal/mol). The total binding energy for the Vernolide is the lowest (−8.61 kcal/mol) compared to Neoandrographolide (−4.23 kcal/mol) and Ritonavir (−6.47 kcal/mol) hence it is the suggested compound that bind to 3CL<sup>PRO</sup>.

The results shown in Fig. 5 supports previous observations. The three complexes were equilibrated for 50 ns as reflected from the flattened Root Mean Square Deviation (RMSD) and the Radius of Gyration (RoG) curves in Fig. 5A. The Root Mean Square Fluctuations (RMSF) in Å was plotted for the apo-3CL<sup>PRO</sup> (red line) and the three complexes (3CL<sup>PRO</sup>-Ritonavir (blue line), 3CL<sup>PRO</sup>-Neoandrographolide (orange line), and 3CL<sup>PRO</sup>-Vernolide (gray line) (Fig. 5B).

Two regions of the RMSF plots that have higher fluctuations (greater than 2 Å) in addition to the N and C termini, are the S46–P52 region (red cartoon) and the T190–A193 region (yellow cartoon). As shown in the RMSF at the S46–P52 region, the apo-3CL<sup>PRO</sup> shows higher fluctuations than the 3CL<sup>PRO</sup>-Ritonavir (blue line), 3CL<sup>PRO</sup>-Neoandrographolide (orange line) and 3CL<sup>PRO</sup>-Vernolide (gray line) complexes. This region forms a loop that is important in substrate recognition since its presence near the protein's active site (blue sticks). The stabilization effect of the ligand binding to S46–P52 region of the protein is due to C44 (magenta sticks) in the case of 3CL<sup>PRO</sup>-Neoandrographolide, which has the most contribution in the protein-ligand binding (−0.60 kcal/mol). In comparison, H41 and C145 (blue sticks) are the most contributed residues in the binding in 3CL<sup>PRO</sup>-Vernolide (−2.16 kcal/mol). Additionally, the residues D48 and M49 (see Fig. 5C) in the case of 3CL<sup>PRO</sup>-Neoandrographolide complex (orange line) show lower RMSF value (2.1 Å) compared to other complexes (3.2 Å) and the Apo form (4.2 Å). So, the stabilization of the S46–P52 loop is more observed in the case of Neoandrographolide than other compounds which in turn is more stable

than the Apo protein.

## 4. Conclusion

Structure-based virtual screening of our in-house library of *Vernonia amygdalina*- and *Occimum gratissimum*-derived compounds against 3CL<sup>PRO</sup> revealed two drug-like terpenoid structures viz: neoandrographolide and vernolide, alongside other phytochemicals as promising non-covalent inhibitors of SARS-CoV-2 3CL<sup>PRO</sup>. These terpenoid structures were found accommodated within the substrate-binding pocket, and interacted with the catalytic dyad, the oxyanion loop (residues 138–145), and the S1/S2 subsites of the enzyme active site. With the aid of an array of hydrogen bonds and hydrophobic interactions with residues 142–145, these phytochemicals may stabilize the conformation of the flexible oxyanion loop; and thereby interfere with the tetrahedral oxyanion intermediate formation during proteolytic cleavage. Binding affinity calculation using Molecular Mechanics Generalized Born Surface Area (MM-GBSA) and Root Mean Square Fluctuations (RMSF) analyses through Molecular Dynamics Simulations (MDS) further revealed that the terpenoid-enzyme complexes exhibit strong interactions and structural stability, which could be adapted for experimental models towards development of preventive nutraceuticals, food supplement, and antiviral drugs in coronavirus diseases.

## Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Declaration of competing interest

No potential conflict of interest is reported by the authors.

## Acknowledgements

The authors acknowledge with thanks resources offered by the PhytoBioNet platform. MDS and MM-GBSA calculations are done on the Bibliotheca Alexandrina HPC facility, Alexandria, Egypt.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.compbimed.2021.104671>.

## References

- [1] C. Liu, Q. Zhou, Y. Li, L.V. Garner, S.P. Watkins, L.J. Carter, J. Smoot, A.C. Gregg, A.D. Daniels, S. Jervay, D. Albai, Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases, *ACS Cent. Sci.* 6 (2020) 315–331, <https://doi.org/10.1021/%2Facscentsci.0c00272>.
- [2] H. Wang, X. Li, T. Li, S. Zhang, L. Wang, X. Wu, J. Liu, The genetic sequence, origin, and diagnosis of SARS-CoV-2, *Eur. J. Clin. Microbiol. Infect. Dis.* 39 (2020) 1629–1635, <https://doi.org/10.1007/s10096-020-03899-4>.
- [3] M. Fani, A. Teimoori, S. Ghafari, Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections, *Future Virol.* (2020), <https://doi.org/10.2217/fvl-2020-0050>.
- [4] M. Pal, G. Berhanu, C. Desalegn, V. Kandi, Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): an update, *Cureus* 12 (2020), <https://doi.org/10.7759/%2Fcureus.7423>.
- [5] M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, T. S. Schiergens, G. Herrler, N.-H. Wu, A. Nitsche, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, *Cell* 181 (2020) 271–280, <https://doi.org/10.1016/j.cell.2020.02.052>.
- [6] L. Zhang, D. Lin, X. Sun, U. Curth, C. Drosten, L. Sauerhering, S. Becker, K. Rox, R. Hilgenfeld, Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved  $\alpha$ -ketoamide inhibitors, *Science* (New York, N.Y.) 368 (2020) 409–412, <https://doi.org/10.1126/%2Fscience.abb3405>.
- [7] M. Shahid, S. Shahzad-Ul-Hussan, Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2, *J. Struct. Biol.* 213 (2020), <https://doi.org/10.1016/%2Fj.jsb.2020.107690>.

- [8] S. Ullrich, C. Nitsche, The SARS-CoV-2 main protease as drug target, *Bioorg. Med. Chem. Lett* 30 (2020) 127377, <https://doi.org/10.1016/j.bmcl.2020.127377>, 127377.
- [9] G.A. Gyebi, A.P. Adegunloye, I.M. Ibrahim, O.M. Ogunyemi, S.O. Afolabi, O. B. Ogunro, Prevention of SARS-CoV-2 cell entry: insight from in silico interaction of drug-like alkaloids with spike glycoprotein, human ACE2, and TMPRSS2, *J. Biomol. Struct. Dyn.* (2020) 1–25, <https://doi.org/10.1080/07391102.2020.1835726>.
- [10] B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan, L. Ruan, B. Song, Y. Cai, M. Wei, A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19, *N. Engl. J. Med.* 382 (2020) 1787–1799, <https://doi.org/10.1056/nejmoa2001282>.
- [11] S. Panyod, C.-T. Ho, L.-Y. Sheen, Dietary therapy and herbal medicine for COVID-19 prevention: a review and perspective, *J Tradit Complement Med* 10 (2020) 420–427, <https://doi.org/10.1016/j.jtcm.2020.05.004>.
- [12] S. Gupta, V. Singh, P.K. Varadwaj, N. Chakravarty, A.V.S.K.M. Katta, S.P. Lekkala, G. Thomas, S. Narasimhan, A.R. Reddy, V.B. Reddy Lachagari, Secondary metabolites from spice and herbs as potential multitarget inhibitors of SARS-CoV-2 proteins, *J. Biomol. Struct. Dynam.* (2020) 1–20, <https://doi.org/10.1080/07391102.2020.1837679>.
- [13] A.J. Akindede, F.O. Agunbiade, M.O. Sofidiya, O. Awodele, A. Sowemimo, O. Ademilua, M.O. Akinleye, I.O. Ishola, I. Orabueze, COVID-19 pandemic: a case for phytomedicines, *Natural Product Communications* 15 (2020), 1934578X20945086.
- [14] K.T. Choy, A.Y. Wong, P. Kaewpreedee, S.F. Sia, D. Chen, K.P.Y. Hui, D.K.W. Chu, M.C.W. Chan, P.P. Cheung, X. Huang, M. Peiris, H.L. Yen, Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro, *Antivir. Res.* 178 (2020) 104786.
- [15] A. Pandey, M.K. Khan, M. Hamurcu, S. Gezgin, Natural plant products: a less focused aspect for the COVID-19 viral outbreak, *Front. Plant Sci.* 11 (2020).
- [16] G.A. Gyebi, O.B. Ogunro, A.P. Adegunloye, O.M. Ogunyemi, S.O. Afolabi, Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL(pro)): an in silico screening of alkaloids and terpenoids from African medicinal plants, *J. Biomol. Struct. Dynam.* 39 (2021) 3360–3408, <https://doi.org/10.1080/07391102.2020.1764868>.
- [17] G.O. Igile, W. Oleszek, M. Jurzysta, S. Burda, M. Fafunso, A.A. Fasanmade, Flavonoids from Vernonia amygdalina and their antioxidant activities, *J. Agric. Food Chem.* 42 (1994) 2445–2448, <https://doi.org/10.1021/jf00047a015>.
- [18] I.T. Oyeyemi, A.A. Akinlabi, A. Adewumi, A.O. Aleshinloye, O.T. Oyeyemi, Vernonia amygdalina: a folkloric herb with anthelmintic properties, *Beni-Suef University Journal of Basic and Applied Sciences* 7 (2018) 43–49, <https://doi.org/10.1016/j.bjbas.2017.07.007>.
- [19] D. Nittya, K. Suresh, A review on ethno-medicinal uses and pharmacology of Vernonia cinerea Less, *Nat. Prod. Res.* 29 (2014) 1102–1117, <https://doi.org/10.1080/14786419.2014.981814>.
- [20] M.K. Oladunmoye, O. Afolabi, B. Oladejo, I.A. Amoo, B. Osho, Derivatized extracts from aframomum melegueta K. Schum. And Vernonia amygdalina delile contain organic compounds that showed antiviral effects against atypical fowl pox virus (FPV kabete), *J. Antivir. Antiretrovir.* 11 (2020).
- [21] B.J. Oso, O.M. Ogunyemi, Assessment of in vitro biological properties of aqueous extracts of *Murraya koenigii*(L.) Spreng, *Thymus vulgaris* L., and *Ocimum gratissimum* L. leaves, *Croat. J. Food Sci. Technol.* 12 (2020), <https://doi.org/10.17508/CJFST.2020.12.2.13>.
- [22] S. Pandey, S. Singh, N. Kumar, R. Botany, ANTIVIRAL, antiprotozoal, antimalarial and insecticidal activities of *Ocimum gratissimum* L., *Asian J. Pharmaceut. Res. Dev.* 5 (2017) 1–9.
- [23] G.N. Bongo, A. Matondo, C. Mbadiko Mutunda, C. Inkoto, E. Lengbiye, C. Kabengele, D. Tshibangu, D. Tshilandaa, K.-T.-N. Ngbolua, P.T. Mpiana, *Ocimum* species as potential bioresources against COVID-19: a review of their Phytochemistry and antiviral activity, *International Journal of Pathogen Research* 5 (2020) 42–54.
- [24] C.O. Esimone, O. Omobuwajo, C. Amadi, M.U. Adiku, R. Edrada-Ebel, C. Chaidir, Antiviral potentials of Nigerian aframomum melagueta roscoe and piper guineense schum. And thonn, *Nigerian Journal of Natural Product and Medicine* 10 (2006) 51–54.
- [25] G.A. Gyebi, A.P. Adegunloye, I.M. Ibrahim, O.M. Ogunyemi, S.O. Afolabi, O. B. Ogunro, Prevention of SARS-CoV-2 cell entry: insight from in silico interaction of drug-like alkaloids with spike glycoprotein, human ACE2, and TMPRSS2, *J. Biomol. Struct. Dynam.* (2020) 1–25.
- [26] L.S. Borquaye, E.N. Gasu, G.B. Ampomah, L.K. Kyei, M.A. Amah, C.N. Mensah, D. Nartey, M. Commodore, A.K. Adomako, P. Acheampong, J.O. Mensah, D. B. Marmor, C.I. Aboagye, Alkaloids from *cryptolepis sanguinolenta* as potential inhibitors of SARS-CoV-2 viral proteins: an in silico study, *BioMed Res. Int.* 2020 (2020), 5324560.
- [27] E.H.B. Maia, L.C. Assis, T.A. de Oliveira, A.M. da Silva, A.G. Taranto, Structure-based virtual screening: from classical to artificial intelligence, *Frontiers in Chemistry* 8 (2020).
- [28] N.M. O'Boyle, M. Banck, C.A. James, C. Morley, T. Vandermeersch, G. R. Hutchison, Open Babel: an open chemical toolbox, *J. Cheminf.* 3 (2011) 33.
- [29] O. Trott, A.J. Olson, AutoDock Vina, Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, *J. Comput. Chem.* 31 (2010) 455–461.
- [30] H. Berman, K. Henrick, H. Nakamura, Announcing the worldwide protein Data Bank, *Nat. Struct. Biol.* 10 (2003) 980.
- [31] COVID-19 main protease with unliganded active site. <http://www.rcsb.org/structure/6Y842020>, 2020 accessed 13 June 2020, 3.
- [32] S. Jo, T. Kim, V.G. Iyer, W. Im, CHARMM-GUI: a web-based graphical user interface for CHARMM, *J. Comput. Chem.* 29 (2008) 1859–1865.
- [33] J.C. Phillips, R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, E. Villa, C. Chipot, R. D. Skeel, L. Kale, K. Schulten, Scalable molecular dynamics with NAMD, *J. Comput. Chem.* 26 (2005) 1781–1802.
- [34] W. Humphrey, A. Dalke, K. Schulten, VMD: visual molecular dynamics, *J. Mol. Graph.* 14 (33–38) (1996) 27–38.
- [35] P. Mark, L. Nilsson, Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K, *J. Phys. Chem.* 105 (2001) 9954–9960.
- [36] E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E. Ferrin, UCSF Chimera—a visualization system for exploratory research and analysis, *J. Comput. Chem.* 25 (2004) 1605–1612.
- [37] S. Jo, T. Kim, V.G. Iyer, W. Im, CHARMM-GUI: a web-based graphical user interface for CHARMM, *J. Comput. Chem.* 29 (2008) 1859–1865, <https://doi.org/10.1002/jcc.20945>. PMID: 18351591.
- [38] B.R. Brooks, C.L. Brooks III, A.D. Mackerell Jr., L. Nilsson, R.J. Petrella, B. Roux, Y. Won, G. Archontis, C. Bartels, S.J. Boresch, et al., CHARMM: the biomolecular simulation program, *J. Comput. Chem.* 30 (2009) 1545–1614, <https://doi.org/10.1002/jcc.21287>.
- [39] J. Lee, X. Cheng, J.M. Swails, M.S. Yeom, P.K. Eastman, J.A. Lemkul, S. Wei, J. Buckner, J.C. Jeong, Y.J. Qi, et al., CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field, *J. Chem. Theory Comput.* 12 (2016) 405–413, <https://doi.org/10.1021/acs.jctc.5b00935>.
- [40] B.R. Miller III, T.D. McGee Jr., J.M. Swails, N. Homeyer, H. Gohlke, A.E. Roitberg, MMPBSA.py: an efficient program for end-state free energy calculations, *J. Chem. Theory Comput.* 8 (2012) 3314–3321, <https://doi.org/10.1021/ct300418h>.
- [41] D.S.C.D.A. Case, T.E. Cheatham III, T.A. Darden, R.E. Duke, T.J. Giese, H. Gohlke, A.W. Goetz, D. N.H. Greene, S. Izadi, A. Kovalenko, T.S. Lee, S. LeGrand, P. Li, C. Lin, J. Liu, T. Luchko, R. Luo, K.M.M.D. Mermelstein, G. Monard, H. Nguyen, I. Omelyan, A. Onufriev, F. Pan, R. Qi, D.R. Roe, A. C.S. Roitberg, C.L. Simmerling, W.M. Botello-Smith, J. Swails, R.C. Walker, J. Wang, R.M. Wolf, X. L.X. Wu, D. M. York, P.A. Kollman, AMBER 2017, University of California, San Francisco, 2017.
- [42] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A. J. Olson, AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility, *J. Comput. Chem.* 30 (2009) 2785–2791.
- [43] M.D. Hanwell, D.E. Curtis, D.C. Lonie, T. Vandermeersch, E. Zurek, G.R. Hutchison, Avogadro: an advanced semantic chemical editor, visualization, and analysis platform, *J. Cheminf.* 4 (2012) 17.
- [44] J. Fliege, B.F. Svaiter, Steepest descent methods for multicriteria optimization, *Math. Methods Oper. Res.* 51 (2000) 479–494.
- [45] A.K. Rappe, C.J. Casewit, K.S. Colwell, W.A. Goddard, W.M. Skiff, UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations, *J. Am. Chem. Soc.* 114 (1992) 10024–10035.
- [46] S. Salentin, S. Schreiber, V. Haupt, M. Adasme, M. Schroeder, PLIP: fully automated protein-ligand interaction profiler, *Nucleic Acids Res.* 43 (2015).
- [47] A. Daina, O. Michielin, V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, *Sci. Rep.* 7 (2017) 42717.
- [48] F. Cheng, W. Li, Y. Zhou, J. Shen, Z. Wu, G. Liu, P.W. Lee, Y. Tang, admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties, *J. Chem. Inf. Model.* 52 (2012) 3099–3105.
- [49] A. Trezza, D. Iovinelli, A. Santucci, F. Prisci, O. Spiga, An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors, *Sci. Rep.* 10 (2020), <https://doi.org/10.1038/s41598-020-70863-9>.
- [50] H. Yang, M. Yang, Y. Ding, Y. Liu, Z. Lou, Z. Zhou, L. Sun, L. Mo, S. Ye, H. Pang, G. F. Gao, K. Anand, M. Bartlam, R. Hilgenfeld, Z. Rao, The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor, *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003) 13190–13195, <https://doi.org/10.1073/pnas.1835675100>.
- [51] Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, B. Zhang, X. Li, L. Zhang, C. Peng, Structure of M pro from SARS-CoV-2 and discovery of its inhibitors, *Nature* 582 (2020) 289–293, <https://doi.org/10.1038/s41586-020-2223-y>.
- [52] J.Y. Li, Z. You, Q. Wang, Z.J. Zhou, Y. Qiu, R. Luo, X.Y. Ge, The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future, *Microb. Infect.* 22 (2020) 80–85, <https://doi.org/10.1016/j.micinf.2020.02.002>.
- [53] J. Wang, Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study, *J. Chem. Inf. Model.* 20 (2020), <https://doi.org/10.26434/chemrxiv.11875446>.
- [54] O.M. Ogunyemi, G.A. Gyebi, A.A. Elfiky, S.O. Afolabi, O.B. Ogunro, A. P. Adegunloye, I.M. Ibrahim, Alkaloids and flavonoids from African phytochemicals as potential inhibitors of SARS-Cov-2 RNA-dependent RNA polymerase: an in silico perspective, *Antiviral Chem. Ther.* 28 (2020), <https://doi.org/10.1177/2040206620984076>.
- [55] R. De Paris, C.V. Quevedo, D.D. Ruiz, O. Norberto de Souza, R.C. Barros, Clustering Molecular Dynamics Trajectories for Optimizing Docking Experiments, *Computational intelligence and neuroscience*, 2015, <https://doi.org/10.1155/2015/916240>.
- [56] H.-x. Su, S. Yao, W.-f. Zhao, M.-j. Li, J. Liu, W.-j. Shang, H. Xie, C.-Q. Ke, H.-c. Hu, M.-n. Gao, H. Liu, J.-s. Shen, W. Tang, L. Zhang, G.-f. Xiao, L. Ni, D.-w. Wang, J.-P. Zuo, Y.-c. Xu, Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients, *Acta Pharmacol. Sin.* 41 (2020) 1167–1177, <https://doi.org/10.1038/s41401-020-0483-6>.



- [57] Z. Jin, Y. Zhao, Y. Sun, Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur, *Nat. Struct. Mol. Biol.* 27 (2020) 529–532, <https://doi.org/10.1038/s41594-020-0440-6>.
- [58] C. Lipinski, a, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, *Adv. Drug Deliv. Rev.* 46 (2001) 3, [https://doi.org/10.1016/s0169-409x\(00\)00129-0](https://doi.org/10.1016/s0169-409x(00)00129-0).
- [59] D.F. Veber, S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward, K.D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates, *J. Med. Chem.* 45 (2002) 2615–2623, <https://doi.org/10.1021/jm020017n>.
- [60] A.K. Ghose, V.N. Viswanadhan, J.J. Wendoloski, A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases, *J. Combin. Chem.* 1 (1999) 55–68, <https://doi.org/10.1021/cc9800071>.
- [61] W.J. Egan, K.M. Merz, J.J. Baldwin, Prediction of drug absorption using multivariate statistics, *J. Med. Chem.* 43 (2000) 3867–3877, <https://doi.org/10.1021/jm000292e>.
- [62] Y.C. Martin, A bioavailability score, *J. Med. Chem.* 48 (2005) 3164–3170, <https://doi.org/10.1021/jm0492002>.
- [63] J.D. Hughes, J. Blagg, D.A. Price, S. Bailey, G.A. DeCrescenzo, R.V. Devraj, E. Ellsworth, Y.M. Fobian, M.E. Gibbs, R.W. Gilles, Physicochemical drug properties associated with in vivo toxicological outcomes, *Bioorg. Med. Chem. Lett* 18 (2008) 4872–4875, <https://doi.org/10.1016/j.bmcl.2008.07.071>.
- [64] C.A. Larregieu, L.Z. Benet, Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements, *AAPS J.* 15 (2013) 483–497, <https://doi.org/10.1208/s12248-013-9456-8>.
- [65] J.H. Lin, M. Yamazaki, Role of P-glycoprotein in pharmacokinetics, *Clin. Pharmacokinet.* 42 (2003) 59–98.
- [66] L. Zanin, G. Saraceno, P.P. Panciani, G. Renisi, L. Signorini, K. Migliorati, M. M. Fontanella, SARS-CoV-2 can induce brain and spine demyelinating lesions, *Acta Neurochir.* (2020) 1–4, <https://doi.org/10.1007/s00701-020-04374-x>.
- [67] E. Raschi, V. Vasina, E. Poluzzi, F. De Ponti, The hERG K<sup>+</sup> channel: target and antitarget strategies in drug development, *Pharmacol. Res.* 57 (2008) 181–195, <https://doi.org/10.1016/j.phrs.2008.01.009>.
- [68] J.M. Kratz, U. Grienke, O. Scheel, S.A. Mann, J.M. Rollinger, Natural products modulating the hERG channel: heartaches and hope, *Nat. Prod. Rep.* 34 (2017) 957–980, <https://doi.org/10.1039/c7np00014f>.
- [69] J. Shen, F. Cheng, Y. Xu, W. Li, Y. Tang, Estimation of ADME properties with substructure pattern recognition, *J. Chem. Inf. Model.* 50 (2010) 1034–1041, <https://doi.org/10.1021/ci100104j>.

**Dr. Gideon A. Gyebi** is currently a lecturer at the Department of Biochemistry, Faculty of Science and Technology Bingham University, Karu, Nasarawa, Nigeria. He obtained his Ph.D in Biochemistry in cancer chemoprevention and toxicology from the Department of Biochemistry, University of Ilorin, Kwara state, Nigeria. He was a former faculty member of the College of Natural and Applied Sciences, Salem University, Nigeria. He was a visiting researcher to the Department of Chemistry and Biomolecular Sciences, Faculty of Engineering, and the Anaerobic Research Unit of Gifu University, (1-1 Yanagido Gifu) Japan. His research interests are natural product Chemistry, Bioinformatics malaria and cancer chemotherapy. He is a pioneer member of the PhytoBioNet: Phytochemistry and Bioinformatic Network.

**Dr. Abdo A. Elfiky** I'm working in the Biophysics Department, Faculty of Sciences, Cairo University, Giza, Egypt as a Lecturer starting from the year 2013 then Associate Professor 2019. My interest in Molecular Biophysics pushes me to work in Structural Bioinformatics and Drug Design to find potent inhibitors against viral and pathogenic fungal proteins utilizing in silico techniques. During the past 6 years, I focused my research on polymerase protein due to its vital role in the life cycle of the pathogenic organisms. I studied also other

proteins like protease, estrogen receptors and kinases. Currently, I'm working on fungal CoTn kinase family proteins crucial for Mucormycosis virulence and the unfolded protein response master chaperone protein, GRP78.

**Oludare M. Ogunyemi** is an advanced PhD candidate in the Department of Biochemistry, College of Medicine, University of Ibadan and currently a lecturer in the Department of Biochemistry, Salem University, Nigeria. He is a recipient of several awards which include the African-German Network of Excellence in Science Mobility grant, 2016. He was a visiting pre-doctoral researcher to the Food Security and Safety Research Niche, North-West University, Mafikeng, South Africa. He is a reviewer of manuscripts for reputable journals. He is a pioneer member of the Phytochemistry and Bioinformatic Network (PhytoBioNet). His hopes to conduct research in the area of Human nutraceuticals and bioinformatics.

**Ibrahim Mohamed Ibrahim** is a master degree candidate in Department of Biophysics, Cairo University, Egypt. He is a researcher in Dr. Abdo A. Elfiky research group. He has published several papers related to structural bioinformatics.

**Dr. Adegbenro P. Adegunloye** is a Clinical Biochemist with keen interest in malaria chemotherapy and biochemical toxicology. He obtained his Ph.D. in Biochemistry from University of Ilorin, Nigeria. He was a former lecturer at Wesley University of Science and Technology, Ondo, Nigeria.

**Professor Joseph O. Adebayo** is currently a professor of clinical biochemistry and biochemical toxicology at the Department of Biochemistry, Faculty of Life Sciences, University of Ilorin, Nigeria. He obtained his Ph.D in Biochemistry (Clinical option) from the University of Ilorin, Kwara state, Nigeria. He is a former postdoctoral fellow at the Instituto Ren'e Rachou, FIOCRUZ, Belo Horizonte MG, Brasil. His research interests are malaria chemotherapy and diagnosis. He has presented various academic as well as research-based papers at several national and international conferences including Society of Toxicology USA. He has supervised several Ph.D students, one of such is Dr. Gideon A. Gyebi.

**Professor C.O.O Olaiya** is a professor and the Director of Nutritional and Industrial Biochemistry Research Unit, Department of Biochemistry, College of Medicine, University of Ibadan, Nigeria. He obtained his Ph.D. in Biochemistry from the University of Ibadan, Nigeria. He is a recipient of several awards such as the TWAS Postdoctoral Research Fellowship Award, 2009 among others. He was a former postdoctoral fellow at the International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan and Visiting Professor at Kampala International University, Uganda. His current research interests include: Plant metabolites and biofortification of food crops, modulation of plant responses to abiotic stress, fermentation technology, and nutraceuticals. He has presented various academic as well as research-based papers at many national and international conferences. He has trained and supervised quite a number of Ph.D students to date.

**Joshua O. Ocheje** received his M.Sc. Analytical Chemistry from the University of Ibadan and currently works as a Lecturer in the Department of Pure and Industrial Chemistry, Nnamdi Azikiwe University, Nigeria. He is a recipient of the National Youth Service Corps (NYSC) Presidential Honors Award 2019. His research interests include the use of biochemistry and X-ray crystallography to study the structure and function of enzymes and other important proteins as drug targets.

**Modupe Mercy Fabusiwa** recently completed her B.Sc. degree in Biochemistry from Salem University, Nigeria. She has published papers related to food and nutritional biochemistry.